Allergan to buy MAP for $958 million

Wall Street Journal

Allergan said it will buy MAP Pharmaceuticals in a $958 million deal that would help the Botox maker expand sales of medical treatments.

Letter
to the
Editor

Send us a letter

Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

Recommended for You
U.S. Food and Drug Administration (FDA)
Upcoming FDA draft on pulse oximetry's racial bias draws questions
Most Popular
1
UnitedHealthcare CEO’s killing unleashes rage against insurers
2
How the new Trump administration could hurt provider finances
3
What to expect in the primary care market in 2030
4
Digital health companies face time crunch with employer contracts
5
'Transparent' CVS, Express Scripts, OptumRx PBMs draw interest